NEW YORK, NY / ACCESSWIRE / March 11, 2020 / Clearside Biomedical, Inc. (NASDAQ:CLSD) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 11, 2020 at ...
Q4 2019 Clearside Biomedical Inc Earnings Call
Clearside Biomedical, Inc. (CLSD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Clearside Biomedical, Inc. (CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that its fourth quarter and full year 2019 financial results will be reported on Wednesday, March 11, 2020 after the close of the financial markets. The live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. The live call can be accessed by dialing (844) 263-8310 (domestic) or (213) 358-0959 (international) and entering conference code: 2462408.
Clearside Biomedical, Inc. (CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today the formation of a Scientific Advisory Board comprised of world-renowned retinal physicians to advise on the Company’s research and development programs. David S. Boyer, M.D. is a clinician, surgeon, and educator at the Retina-Vitreous Associates Medical Group in Southern California.
Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and Bausch + Lomb, its leading global eye health business, and Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that Ophthalmology, the peer-reviewed journal of the American Academy of Ophthalmology, has published results from the randomized, controlled, double-masked Phase 3 clinical trial (PEACHTREE study) of XIPERETM (triamcinolone acetonide suprachoroidal injectable suspension), an investigational therapy with a proposed indication of treatment of macular edema associated with uveitis.1
Clearside Biomedical, Inc. (CLSD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Clearside Biomedical, Inc. (CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that Nancy J. Hutson, Ph.D. has been appointed to the Company's Board of Directors, effective April 21, 2020. “The addition of Nancy Hutson to our Board of Directors comes at a key time as we are expanding our research and development pipeline and preparing to initiate a clinical program targeting the treatment of wet age-related macular degeneration with CLS-AX,” said William Humphries, Chairman of the Clearside Board of Directors.
ALPHARETTA, Ga., Feb. 26, 2020 -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and.
As of late, it has definitely been a great time to be an investor in Clearside Biomedical.
Clearside Biomedical, Inc. (CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today an update to the XIPERE™ (triamcinolone acetonide suprachoroidal injectable suspension) New Drug Application (NDA) resubmission timeline and to its commercialization and development partnership with Bausch Health Companies Inc. (“Bausch Health”) and Bausch + Lomb, its leading global eye health business. As previously disclosed, the contract manufacturing organization (CMO) for XIPERE has been completing certain requalification activities within its facility.
Clearside Biomedical, Inc. (CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, today reported financial results for the first quarter ended March 31, 2020. NDA resubmission timeline for XIPERE (triamcinolone acetonide suprachoroidal injectable suspension) is currently targeted for the fourth quarter of 2020 based on recent manufacturing updates.
ALPHARETTA, Ga., April 08, 2020 -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and.
Clearside Biomedical Inc (CLSD) delivered earnings and revenue surprises of 22.22% and 2.43%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Clearside Biomedical, Inc. (CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that multiple oral presentations on Clearside’s pipeline and proprietary SCS Microinjector™ targeting the suprachoroidal space were given this month at the 17th Annual Angiogenesis Meeting and 43rd Annual Macula Society Meeting. “February was an extremely productive month for Clearside as our pipeline continues to gain exposure within the physician community, resulting in multiple oral presentations on our programs,” said Thomas A. Ciulla, M.D., MBA, Chief Medical Officer.
Clearside Biomedical, Inc. (CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that Arctic Vision, a company focused on developing and commercializing innovative ophthalmology therapies in China and Asia, has acquired an exclusive license for the commercialization and development of XIPERE™ (triamcinolone acetonide suprachoroidal injectable suspension) in Greater China (mainland China, Hong Kong, Macau and Taiwan) and South Korea. XIPERE is a proprietary suspension of the corticosteroid triamcinolone acetonide formulated for suprachoroidal administration via Clearside’s proprietary SCS Microinjector™ that is being investigated as a targeted treatment of macular edema associated with uveitis.
Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of -75.00% and -67.06%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Clearside Biomedical, Inc. (CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that George Lasezkay, Pharm.D., J.D., has been appointed President and Chief Executive Officer. In less than one year, we have concluded preclinical studies to advance CLS-AX (axitinib injectable suspension) into the clinic and have added multiple partnerships for our suprachoroidal space injection platform, including two key licensing agreements for the commercialization of our late stage asset, XIPERE™ (triamcinolone acetonide suprachoroidal injectable suspension). “I am excited about having the opportunity to continue working closely with the Clearside team and I am grateful to the Board for their confidence and support,” said George Lasezkay, Pharm.D., J.D., President and CEO, Clearside Biomedical.
- IND Submission for CLS-AX (axitinib injectable suspension) On Track for Mid-2020 -- Greater China Licensing Partnership and Updated NDA Resubmission Timeline for XIPERE™.
ALPHARETTA, Ga., Feb. 05, 2020 -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and.